Long Term PPI Use: Safety and Stopping

← Patient Education

Long term PPI use is one of the most common medication questions adults in Arlington, Annandale, and the rest of Northern Virginia bring to a gastroenterologist. The story is usually the same. A proton pump inhibitor, or PPI, was started for heartburn or after a hospital stay, it worked, and the refills kept coming. Years later a news story, a pharmacy handout, or a relative raises the question of whether it is safe to keep taking. This guide explains what the research on long term PPI use shows, who needs to stay on a PPI, who may be able to step down or stop, and what stopping usually feels like.

This article is general education, not medical advice. Do not stop or change a prescribed medication on the basis of an article. That decision belongs in a conversation with a physician who knows why you take it.

What counts as long term PPI use

PPIs are medicines that lower the amount of acid the stomach makes. The group includes omeprazole, esomeprazole, lansoprazole, dexlansoprazole, pantoprazole, and rabeprazole. Several are sold over the counter as well as by prescription.

There is no single definition of long term PPI use, but the American Gastroenterological Association (AGA), in its 2022 clinical practice update on de-prescribing PPIs, treats anything beyond 8 weeks as long term. That is shorter than most people expect, and it reflects how the medicines were studied. The AGA notes that the great majority of trials showing that PPIs work tested them for 4 to 12 weeks, or for no more than 6 to 12 months when the goal was to keep a healed condition from coming back.

The over-the-counter label is shorter still. The Drug Facts panel on nonprescription omeprazole describes a 14-day course for frequent heartburn, repeated no more often than every 4 months unless a doctor directs otherwise. Taking a pharmacy-shelf PPI daily for years is long term PPI use that no physician may ever have reviewed.

Long term PPI use is also very common. According to the AGA update, studies have found that 7 to 15 percent of patients are using a PPI at any given time, rising to about 40 percent of those 70 and older, and about one quarter of people who start a PPI are still taking it a year later.

Is long term PPI use safe? What the research shows

The short version from the major gastroenterology societies is that PPIs are generally safe, that most of the frightening headlines rest on weak evidence, and that a medicine with no remaining purpose is still not worth taking. Each part of that sentence matters.

Where the worrying headlines come from

Over the past two decades, studies have linked PPIs to a long list of conditions. The American College of Gastroenterology (ACG), in its 2022 clinical guideline on GERD, names them directly: intestinal infections, pneumonia, stomach cancer, osteoporosis-related fractures, chronic kidney disease, deficiencies of certain vitamins and minerals, heart attacks, strokes, dementia, and early death.

Nearly all of those links come from observational studies. Researchers look back at large groups of people, compare those who took a PPI with those who did not, and count who became ill. The weakness of that design is that people who take PPIs differ from people who do not. They tend to be older, to have more medical conditions, and to take more medications. An observational study can show that two things travel together. It cannot show that one caused the other. The ACG guideline says these studies have flaws, are not considered definitive, and do not establish a cause-and-effect relationship.

What the largest randomized trial found

A randomized trial avoids that problem by assigning people to a medicine or a placebo by chance. The largest one to look at PPI safety was published in the journal Gastroenterology in 2019. It enrolled 17,598 adults with stable heart or blood vessel disease, assigned half to pantoprazole and half to a placebo, and followed them for a median of three years. Every six months the researchers checked for pneumonia, C. diff infection, other intestinal infections, fractures, chronic kidney disease, diabetes, dementia, heart disease, cancer, hospital stays, and deaths.

The two groups differed in one outcome. Intestinal infections other than C. diff occurred in 1.4 percent of the pantoprazole group and 1.0 percent of the placebo group. For every other outcome, including fractures, kidney disease, and dementia, the rates were similar. C. diff infection was about twice as common with pantoprazole, but there were only 13 cases in the entire trial, too few for the difference to be statistically meaningful.

That trial has limits worth stating. Three years is not twenty, and the participants all had cardiovascular disease, so they do not represent every PPI user. It remains the strongest evidence available, and it is why the ACG guideline says that high-quality studies have found PPIs do not significantly increase the risk of any of these conditions except intestinal infections.

What the ACG suggests patients be told

The ACG guideline goes a step further than most and suggests wording for physicians to use with patients. It makes four points: PPIs are the most effective medical treatment for GERD; the studies linking them to serious conditions are flawed and do not prove cause and effect; a small increase in risk cannot be ruled out; and for the treatment of GERD, gastroenterologists generally agree that the well-established benefits of PPIs far outweigh their theoretical risks.

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) describes PPIs in similar terms, as generally safe and effective, with uncommon side effects such as headache, diarrhea, and upset stomach. It adds that research suggests PPIs may raise the chance of C. diff infection and that experts are still studying the effects of taking them for a long time or in high doses.

Side effects listed on the label for long term PPI use

The Food and Drug Administration requires PPI prescribing information to carry several warnings that relate to long term PPI use. They are based largely on reports and observational studies, and most describe uncommon events. The current prescribing information for omeprazole, revised in June 2025, includes these:

• C. diff diarrhea. Observational studies suggest PPIs may be associated with an increased risk, especially in hospitalized patients. Diarrhea that does not improve deserves a call to your doctor. Our guide to C. diff infection explains the condition.
• Bone fracture. Observational studies suggest a possible increase in osteoporosis-related fractures of the hip, wrist, or spine, mainly in people taking multiple daily doses for a year or longer.
• Vitamin B12 deficiency. Daily acid-suppressing treatment for longer than about three years may reduce B12 absorption. The label describes reports of deficiency as rare.
• Low magnesium. Reported rarely, in people treated for at least three months and in most cases after a year.
• Fundic gland polyps. These small stomach polyps become more likely with use beyond one year. The label notes that most people who develop them have no symptoms and that the polyps are found incidentally during an endoscopy. Our page on gastric polyps explains what the different types mean.
• A kidney reaction called acute tubulointerstitial nephritis. This is an uncommon reaction to the drug that can occur at any point during treatment.

Across these warnings the label gives the same instruction: use the lowest dose and the shortest duration appropriate to the condition being treated. That is a statement about matching the medicine to the need. It is not a statement that everyone should stop.

For the everyday side effects, such as headache, nausea, abdominal pain, diarrhea, constipation, and gas, the ACG guideline notes that they occur infrequently, fade when the medicine is stopped, and sometimes are specific to one product, so switching to a different PPI is a reasonable option to discuss.

Do you need extra tests or supplements with long term PPI use

For most people, no. This is one of the more reassuring parts of the guidance on long term PPI use, and it is specific. For people with GERD on a PPI who have no other risk factors, the ACG guideline does not recommend:

• Raising calcium or vitamin D intake, or routine bone density monitoring, in people with no other risk factors for bone disease
• Raising vitamin B12 intake, or routine B12 blood tests, in people with no other risk factors for B12 deficiency
• Routine kidney function tests in people with no other risk factors for kidney disease

The AGA reached the same conclusions in its 2017 review of the risks and benefits of long term PPI use, and added that people on these medicines should not routinely take probiotics to prevent infection.

Magnesium is the one area where official sources differ. The FDA label says health care professionals may consider checking magnesium before and during prolonged treatment, particularly in people who also take digoxin or diuretics. The AGA advised against routine monitoring. The ACG guideline concluded that there is not enough evidence to make a meaningful recommendation either way. In practice this is decided person by person, based on your other medications and health conditions.

"No other risk factors" is the phrase that carries the weight. Someone with osteoporosis, kidney disease, or a strict vegan diet has reasons for monitoring that have nothing to do with a PPI, and those reasons still apply.

Who should stay on a PPI long term

For some conditions, long term PPI use is the treatment, and stopping carries more risk than continuing. The AGA update lists the conditions where a PPI is definitely indicated beyond 8 weeks:

• Barrett's esophagus. The AGA cites evidence that PPIs lower the risk of esophageal cancer in people with this condition and advises against a trial of stopping. See our guide to Barrett's esophagus.
• Severe erosive esophagitis. This means the more serious grades of acid damage seen on endoscopy, called Los Angeles grade C or D. The ACG guideline recommends indefinite maintenance PPI therapy or antireflux surgery for this group, and reports that with grade C disease nearly everyone relapses within six months of stopping.
• Narrowing of the esophagus caused by reflux, called a peptic stricture, or a past esophageal ulcer. Trouble swallowing is the usual symptom. Our guide to difficulty swallowing explains more.
• Eosinophilic esophagitis that has responded to a PPI. The AGA notes that not everyone with this condition needs a PPI, but stopping one that is working may lead to a high rate of recurrence. See eosinophilic esophagitis.
• Protection of the stomach in people at high risk of bleeding. This is discussed below.
• Zollinger-Ellison syndrome, a very rare condition in which the stomach makes far too much acid.
• Idiopathic pulmonary fibrosis, a lung disease, where the AGA considers it reasonable not to target these patients for stopping until better evidence is available.

PPIs that are protecting against bleeding

Many people take a PPI without ever having had heartburn. The medicine was prescribed to protect the stomach lining from another drug. The AGA update describes this as one of the key benefits of PPIs: they markedly reduce the likelihood of bleeding in the upper digestive tract.

The AGA advises that anyone on a PPI be assessed for bleeding risk before stopping is considered, and that people at high risk not have the PPI withdrawn. Drawing on several sets of recommendations from gastroenterology and cardiology organizations, it describes high risk as generally including people who:

• Have had bleeding in the upper digestive tract before, for example from an ulcer
• Take more than one blood-thinning medication, counting both anticoagulants and antiplatelet drugs
• Take aspirin or a nonsteroidal anti-inflammatory drug such as ibuprofen or naproxen and also have another risk factor, such as being older than 60, having a serious medical condition, or taking a second such drug, a blood thinner, or an oral steroid

The AGA points out that these risk factors are often hidden. Daily low-dose aspirin bought over the counter is the usual example. It is one reason a complete medication list, including nonprescription products, matters at any visit where stopping a PPI is discussed.

When long term PPI use may no longer be needed

The other side of the picture is that many people on a PPI have no condition that calls for one. The AGA update cites a large study of outpatient visits in which nearly two thirds of PPI users had no clear documented reason for taking it. Its first piece of advice is that everyone taking a PPI should have the reason reviewed regularly, and its second is that anyone without a definite reason for chronic use should be considered for a trial of stopping.

Situations in which that review often leads to a change include:

• Heartburn that resolved on treatment. For people with typical reflux symptoms that respond to an 8-week course, and who do not have erosive esophagitis or Barrett's esophagus, the ACG guideline recommends an attempt to discontinue the PPI.
• A PPI started in the hospital. The AGA notes that a PPI begun for a short-term reason during a hospital stay may be continued at discharge without anyone reviewing whether it is still needed.
• Throat symptoms treated on a guess. Cough, hoarseness, throat clearing, and a lump-in-the-throat sensation are often treated with a PPI. The AGA cites a randomized trial showing no benefit from PPIs given empirically for these symptoms. Our silent reflux page explains when testing comes first.
• A dose higher than standard. The AGA reports that up to 15 percent of PPI users take more than the standard dose, and advises that most people on twice-daily dosing who do need a PPI be considered for a step down to once daily.
• Symptoms the PPI never clearly helped. That raises a different question, covered in our guide to GERD not responding to medication.

Between "must stay on" and "can stop" sits a large middle group. The AGA classifies reflux that responds to a PPI and returns each time the PPI is stopped, with a normal endoscopy, as a conditional reason for long term PPI use. For these people the ACG guideline advises the lowest dose that controls symptoms, and it describes two alternatives to a daily pill: on-demand use, in which the PPI is taken only when symptoms occur, and stepping down to a milder acid reducer called an H2 blocker. It notes that on-demand use performed as well as continuous use in people without erosive disease, but not in people with erosive esophagitis.

One principle from the AGA update is easy to overlook. It advises that the decision to stop a PPI be based only on the lack of a reason to take it, and not on fear of side effects. A PPI that is preventing bleeding or protecting a damaged esophagus should not be dropped because of an alarming article. The update cites survey research in which nearly 40 percent of PPI users had tried to stop, and 83 percent of those did so without a physician's advice.

How stopping long term PPI use is usually handled

Ending long term PPI use is a medical decision, and the approach depends on why the PPI was started. What follows describes how the societies frame it, so that the conversation with your physician is easier to follow.

Rebound acid: why symptoms can flare after stopping

While a PPI holds acid down, the body responds by raising a hormone called gastrin, which over time increases the stomach's capacity to make acid. As long as the PPI is taken, that extra capacity stays in check. When the PPI is stopped, the stomach can temporarily produce more acid than it did before treatment. This is called rebound acid hypersecretion.

The AGA update describes a trial in which healthy volunteers with no history of heartburn took a PPI for 8 weeks. After stopping, they developed upper digestive symptoms more often than the comparison group in the trial. In other words, the medicine's withdrawal can cause the very symptom it treats, for a while.

This matters because a flare in the first weeks is easy to read as proof that the PPI can never be stopped. The AGA advises that people be told in advance that symptoms may appear in the short term and that this does not necessarily mean a return to a daily PPI. It considers as-needed H2 blockers or antacids, or a PPI taken on demand, reasonable ways to manage that period. The ACG guideline adds a note of balance: rebound has been demonstrated in healthy volunteers, but strong evidence that abruptly stopping increases symptoms in patients is lacking.

How long rebound lasts is not well defined. The AGA notes that the changes in the stomach lining behind it can still be present 8 weeks after stopping and have usually reversed by 6 months. It also advises that severe symptoms persisting more than 2 months after stopping may mean there is a continuing reason for the PPI, or a cause of symptoms that is not acid, and should prompt a return visit.

Tapering compared with stopping all at once

Either approach is considered reasonable. The AGA update describes the one published trial that compared them. People who tapered over three weeks were off the PPI and free of symptoms at six months 31 percent of the time, compared with 22 percent of those who stopped abruptly, a difference that was not statistically significant. The AGA suggests the taper in that trial may have been too short to show a benefit and leaves the choice to the physician and patient.

How often stopping works

Expectations for coming off long term PPI use should be realistic. The ACG guideline reports that about two thirds of people with reflux symptoms and no erosive damage have their symptoms return when the PPI is stopped. The AGA cites a study in which about half of people with uncomplicated GERD who stopped were still off their PPI six months later, and three quarters of those were using an H2 blocker or an antacid for symptom control.

Ending up on a lower dose, on as-needed use, or on a milder medicine is a good result. So is learning, after a fair trial, that you do need the PPI. The AGA's 2017 review names a large hiatal hernia and excess weight around the midsection as things that predispose a person to reflux, and our guides to hiatal hernia and GERD and acid reflux cover the everyday measures that help. For people who want to come off long-term medication and cannot, the NIDDK notes that surgery is an option some consider, with a higher chance of complications than medicine.

When testing helps settle the question

If symptoms return every time the PPI is stopped, testing can show whether reflux is really the cause. The ACG guideline recommends an upper endoscopy when symptoms come back after the medicine is discontinued, ideally after the PPI has been stopped for 2 to 4 weeks. The AGA's 2017 review advises that people with uncomplicated GERD who cannot reduce their PPI consider reflux monitoring before committing to lifelong treatment, to separate true reflux from conditions that feel the same but do not involve acid.

When to call a doctor

Some symptoms should not wait for a routine medication review, whether you are taking a PPI, reducing one, or have stopped. The ACG guideline treats trouble swallowing, unintended weight loss, and signs of bleeding as alarm symptoms that call for endoscopy. Contact a physician promptly for:

• Food sticking, or pain or difficulty with swallowing
• Vomiting blood or material that looks like coffee grounds, or black, tarry stools. Our guide to blood in the stool explains what different colors can mean.
• Weight loss you cannot explain
• Diarrhea that does not improve while taking a PPI
• Severe heartburn that returns after stopping and has not settled within about two months

Chest pain deserves special caution, because heart and digestive symptoms can feel similar. When chest pain is new or severe, it is always safer to seek emergency care than to assume it is reflux.

Further reading is available from the NIDDK on treatment for GERD.

Reviewing long term PPI use in Northern Virginia with GC of NoVA

Gastroenterology Center of Northern Virginia sees patients from Arlington, Annandale, and the surrounding communities who want a clear answer about long term PPI use: whether the medicine is still doing a job, whether the dose is right, and whether a supervised attempt to step down makes sense. Our physicians can review why the PPI was started, look at your other medications for hidden bleeding risk, decide whether an endoscopy or other testing would help, and build a plan with you. We see patients at our Arlington office, next to VHC Health, and our Annandale office, in the Woodburn Medical complex. If this would be your first appointment with a specialist, our guide to a first gastroenterologist visit explains what to bring.

To schedule a visit, contact our Arlington office at (703) 522-7476 or our Annandale office at (703) 560-6106, or learn more at gcofnova.com.

This article is for general education and is not medical advice. Talk with a qualified gastroenterologist about your symptoms, diagnosis, and treatment options.